Akanda's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Akanda (AKAN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Akanda vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
- Scale: Akanda ranks #22 of 37 companies by market capitalization in the Legal Cannabis industry, holding 0.0% of industry market cap.
- Peer revenue share: Akanda accounted for 100.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AKAN Sales vs. its Competitors, Q4 2025
Akanda generated 100.00 % of the combined sales of its peer group.
Akanda's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Akanda Corp | - | No | No | Yes |
| High-Confidence Competitors (7) | ||||
| Similar-Size Competitors (7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AKAN Stock Performance relative to its Competitors
AKAN Stock Performance relative to High-Confidence Competitors
AKAN Stock Performance relative to Similar-Size Competitors
Akanda's Comment on Competition and Industry Peers
Akanda's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| American Tower | Named by the company | 85% |
| CannTrust Holdings | Named by the company | 85% |
| Cresco Labs | Named by the company | 85% |
| MX Towers | Named by the company | 85% |
| RPK | Named by the company | 85% |
| Tilray Portugal, Unipessoal, Lda | Named by the company | 85% |
| Aleafia Health | Named by the company | 85% |
| Bedrocan | Named by the company | 85% |
| Charlotte’s Web | Named by the company | 85% |
| Medigrow | Named by the company | 85% |
| Portocanna SA | Named by the company | 85% |
| The Lyphe Group | Named by the company | 85% |
| 48 North | Named by the company | 85% |
| WeedMD | Named by the company | 85% |
| Aphria | Named by the company | 85% |
| Canopy Growth | Named by the company | 85% |
| Fermaca Networks | Named by the company | 85% |
| National Fiber Networks | Named by the company | 85% |
| Spectrum Cannabis | Named by the company | 85% |
| Torrecom | Named by the company | 85% |
| Aleafia Health/ Red White and Bloom | Named by the company | 85% |
| Canmart | Named by the company | 85% |
| Clever Leaves Portugal Unipessoal Lda | Named by the company | 85% |
| MTP | Named by the company | 85% |
| QMC | Named by the company | 85% |
| the Valens Company | Named by the company | 85% |
| Agrivab Medical Cannabis | Named by the company | 85% |
| Aurora Cannabis | Named by the company | 85% |
| Centennial Towers | Named by the company | 85% |
| ICOM Construcciones | Named by the company | 85% |
| Neutral Networks | Named by the company | 85% |
| Summit1G | Named by the company | 85% |
| Verve Dynamics | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Akanda's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.